These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25904513)

  • 1. [Tigecycline: 10 years of history and still in full force].
    Barberán J; Salso S; Alhambra A
    Rev Esp Quimioter; 2015 Apr; 28(2):61-78. PubMed ID: 25904513
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

  • 3. EUCAST technical note on tigecycline.
    European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee
    Clin Microbiol Infect; 2006 Nov; 12(11):1147-9. PubMed ID: 17063597
    [No Abstract]   [Full Text] [Related]  

  • 4. Tigecycline pharmacokinetic/pharmacodynamic update.
    MacGowan AP
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i11-6. PubMed ID: 18684702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline: a single antibiotic for polymicrobial infections.
    Pankey GA; Steele RW
    Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
    [No Abstract]   [Full Text] [Related]  

  • 6. Tigecycline: place in therapy and important considerations.
    Garrelts JC; Schroeder T
    Am J Health Syst Pharm; 2006 Jul; 63(13):1233. PubMed ID: 16790574
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.
    Peterson LR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):163-4. PubMed ID: 16105559
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
    Curcio D
    J Clin Microbiol; 2008 May; 46(5):1892-3. PubMed ID: 18460636
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tigecycline: antimicrobial action, chemotherapeutic efficacy and adverse reactions].
    Nikitin AV
    Antibiot Khimioter; 2009; 54(1-2):63-6. PubMed ID: 19499721
    [No Abstract]   [Full Text] [Related]  

  • 10. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-defining tigecycline therapy.
    De Rosa FG; Corcione S; Di Perri G; Scaglione F
    New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline in critical care.
    Mullangi PK; Pankey GA
    Crit Care Clin; 2008 Apr; 24(2):365-75, x. PubMed ID: 18361951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline : a critical safety review.
    Kaewpoowat Q; Ostrosky-Zeichner L
    Expert Opin Drug Saf; 2015 Feb; 14(2):335-42. PubMed ID: 25539800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New 'superbug' drug launched in the UK.
    Future Microbiol; 2006 Aug; 1(2):151-5. PubMed ID: 17661658
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline: what is it, and where should it be used?
    Livermore DM
    J Antimicrob Chemother; 2005 Oct; 56(4):611-4. PubMed ID: 16120626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emergence of clinical resistance to tigecycline.
    Sun Y; Cai Y; Liu X; Bai N; Liang B; Wang R
    Int J Antimicrob Agents; 2013 Feb; 41(2):110-6. PubMed ID: 23127485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA; Weaver-Sands DT; Petersen PJ
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009.
    Hawser SP
    J Infect; 2010 May; 60(5):401-2. PubMed ID: 20211200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.